Empowered Funds LLC Has $475,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Empowered Funds LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 86.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,575 shares of the specialty pharmaceutical company’s stock after selling 104,871 shares during the quarter. Empowered Funds LLC’s holdings in Collegium Pharmaceutical were worth $475,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in COLL. Victory Capital Management Inc. raised its stake in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares during the period. Emerald Advisers LLC raised its stake in Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after buying an additional 177,129 shares during the period. JPMorgan Chase & Co. raised its stake in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock valued at $25,591,000 after purchasing an additional 131,835 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after purchasing an additional 116,327 shares during the period.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.91 on Thursday. The stock has a market capitalization of $964.60 million, a price-to-earnings ratio of 12.89 and a beta of 0.82. The business has a 50-day moving average of $31.01 and a 200-day moving average of $33.75. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.39 and a fifty-two week high of $42.29.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.